Smith & Nephew Given “Neutral” Rating at UBS AG (SN)
Smith & Nephew (LON:SN)‘s stock had its “neutral” rating reaffirmed by investment analysts at UBS AG in a note issued to investors on Monday, AR Network reports. They currently have a GBX 780 ($12.50) price objective on the stock. UBS AG’s target price would indicate a potential downside of 2.62% from the stock’s previous close.
SN has been the subject of a number of other recent research reports. Analysts at Numis Securities Ltd reiterated an “add” rating on shares of Smith & Nephew in a research note to investors on Friday. Separately, analysts at Investec upgraded shares of Smith & Nephew to an “add” rating in a research note to investors on Friday. Finally, analysts at Investec upgraded shares of Smith & Nephew to an “add” rating in a research note to investors on Friday. They now have a GBX 832 ($13.34) price target on the stock, up previously from GBX 783 ($12.55). Two investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and four have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of GBX 778.58 ($12.48).
Smith & Nephew (LON:SN) traded up 0.19% on Monday, hitting GBX 802.4999. The stock had a trading volume of 720,400 shares. Smith & Nephew has a 52 week low of GBX 636.50 and a 52 week high of GBX 813.00. The stock has a 50-day moving average of GBX 781. and a 200-day moving average of GBX 770.0. The company’s market cap is £7.199 billion.
Smith & Nephew plc is a global medical devices business operating in the markets for orthopaedic reconstruction and trauma, endoscopy (LON:SN) and advanced wound management.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.